Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.

Polycomb repressive complexes (PRC) are frequently implicated in human cancer, acting either as oncogenes or tumor suppressors. Here, we show that PRC2 is a critical regulator of KRAS-driven non-small cell lung cancer progression. Modulation of PRC2 by either Ezh2 overexpression or Eed deletion enhances KRAS-driven adenomagenesis and inflammation, respectively. Eed-loss-driven inflammation leads to massive macrophage recruitment and marked decline in tissue function. Additional Trp53 inactivation activates a cell-autonomous epithelial-to-mesenchymal transition program leading to an invasive mucinous adenocarcinoma. A switch between methylated/acetylated chromatin underlies the tumor phenotypic evolution, prominently involving genes controlled by Hippo/Wnt signaling. Our observations in the mouse models were conserved in human cells. Importantly, PRC2 inactivation results in context-dependent phenotypic alterations, with implications for its therapeutic application.

[1]  M. Lu,et al.  Ezh2 represses the basal cell lineage during lung endoderm development , 2015, Development.

[2]  I. Vivanco,et al.  Targeting molecular addictions in cancer , 2014, British Journal of Cancer.

[3]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[4]  Randy L. Johnson,et al.  Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ. , 2015, Cell reports.

[5]  C. Peng,et al.  Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells. , 2014, Cancer research.

[6]  H. Hock.  A complex Polycomb issue: the two faces of EZH2 in cancer. , 2012, Genes & development.

[7]  Chuong D. Hoang,et al.  A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. , 2013, Cancer cell.

[8]  S. Orkin,et al.  Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. , 2014, Cell stem cell.

[9]  Shun Lu,et al.  The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2 , 2014, FEBS letters.

[10]  Peter A. Jones,et al.  The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. , 2009, Cancer research.

[11]  Y. Yatabe,et al.  HNF4&agr; as a Marker for Invasive Mucinous Adenocarcinoma of the Lung , 2013, The American journal of surgical pathology.

[12]  H. Jäckle,et al.  A Histone Mutant Reproduces the Phenotype Caused by Loss of Histone-Modifying Factor Polycomb , 2013, Science.

[13]  Tim J. Wigle,et al.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 , 2013, Proceedings of the National Academy of Sciences.

[14]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.

[15]  Joseph Rosenbluh,et al.  KRAS and YAP1 Converge to Regulate EMT and Tumor Survival , 2014, Cell.

[16]  P. Scacheri,et al.  CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing , 2009, Development.

[17]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[18]  D. Peeper,et al.  The essence of senescence. , 2010, Genes & development.

[19]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[20]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[21]  D. Reinberg,et al.  EZH2 couples pancreatic regeneration to neoplastic progression. , 2012, Genes & development.

[22]  Y. Schwartz,et al.  A new world of Polycombs: unexpected partnerships and emerging functions , 2013, Nature Reviews Genetics.

[23]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[24]  B. Ponder,et al.  Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker , 2011, Cancer science.

[25]  P. Hammerman,et al.  Author Correction: EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors , 2018, Nature.

[26]  Christoph Wülfing,et al.  Polycomb Group Protein Ezh2 Controls Actin Polymerization and Cell Signaling , 2005, Cell.

[27]  O. van Tellingen,et al.  Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. , 2007, Cancer cell.

[28]  Kristian Helin,et al.  The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. , 2007, Genes & development.

[29]  L. Wood,et al.  Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors , 2014, Nature Genetics.

[30]  Paul Bertone,et al.  NuRD-mediated deacetylation of H3K27 facilitates recruitment of Polycomb Repressive Complex 2 to direct gene repression , 2011, The EMBO journal.

[31]  Michael R. Green,et al.  An elaborate pathway required for Ras-mediated epigenetic silencing , 2007, Nature.

[32]  Shizuo Akira,et al.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.

[33]  A. Berns,et al.  Multiple cells-of-origin of mutant K-Ras–induced mouse lung adenocarcinoma , 2014, Proceedings of the National Academy of Sciences.

[34]  J. Wrana,et al.  Switch enhancers interpret TGF-β and Hippo signaling to control cell fate in human embryonic stem cells. , 2013, Cell reports.

[35]  M. Serresi,et al.  In vivo RNAi screen for BMI1 targets identifies TGF-β/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis. , 2013, Cancer cell.

[36]  D. Nam,et al.  Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. , 2013, Cancer cell.

[37]  Shan Jiang,et al.  Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer , 2014, Cell.

[38]  Lewis A. Chodosh,et al.  Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis , 2007, Nature Cell Biology.

[39]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[40]  D. Bar-Sagi,et al.  Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. , 2010, Cancer cell.

[41]  S. Levy,et al.  NA-Seq: a discovery tool for the analysis of chromatin structure and dynamics during differentiation. , 2009, Developmental cell.

[42]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[43]  Fernando Ontiveros,et al.  The sterile inflammatory response. , 2010, Annual review of immunology.

[44]  Kristian Helin,et al.  Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes , 2010, Nucleic acids research.

[45]  M. Nieto,et al.  Inflammation and EMT: an alliance towards organ fibrosis and cancer progression , 2009, EMBO molecular medicine.

[46]  M. Krasnow,et al.  Alveolar progenitor and stem cells in lung development, renewal and cancer , 2014, Nature.

[47]  M. Lohuizen,et al.  Context-dependent actions of Polycomb repressors in cancer , 2016, Oncogene.

[48]  A. Alimonti,et al.  Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer , 2014, Nature.

[49]  M. Meyerson,et al.  Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. , 2013, Molecular cell.

[50]  Chi-Hung Huang,et al.  Bmi1 is essential in Twist1-induced epithelial–mesenchymal transition , 2010, Nature Cell Biology.

[51]  Piotr J. Balwierz,et al.  Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. , 2013, Cancer cell.

[52]  Mallika Singh,et al.  Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models , 2010, Nature Biotechnology.

[53]  Kristian Helin,et al.  The Polycomb Group Protein Suz12 Is Required for Embryonic Stem Cell Differentiation , 2007, Molecular and Cellular Biology.

[54]  Kun-Liang Guan,et al.  The emerging roles of YAP and TAZ in cancer , 2015, Nature Reviews Cancer.

[55]  Eric Legius,et al.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies , 2014, Nature.

[56]  Stormy J. Chamberlain,et al.  The Murine Polycomb Group Protein Eed Is Required for Global Histone H3 Lysine-27 Methylation , 2005, Current Biology.

[57]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[58]  Ruiying Zhao,et al.  KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[59]  R. DePinho,et al.  The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus , 1999, Nature.

[60]  Zachary D. Smith,et al.  Lung stem cell self-renewal relies on BMI1-dependent control of expression at imprinted loci. , 2011, Cell stem cell.